GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coya Therapeutics Inc (NAS:COYA) » Definitions » Gross Profit

COYA (Coya Therapeutics) Gross Profit : $3.55 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Coya Therapeutics Gross Profit?

Coya Therapeutics's gross profit for the three months ended in Dec. 2024 was $0.00 Mil. Coya Therapeutics's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $3.55 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Coya Therapeutics's gross profit for the three months ended in Dec. 2024 was $0.00 Mil. Coya Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Coya Therapeutics's Gross Margin % for the quarter that ended in Dec. 2024 was N/A%.

Coya Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


Coya Therapeutics Gross Profit Historical Data

The historical data trend for Coya Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coya Therapeutics Gross Profit Chart

Coya Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
- - - 6.00 3.55

Coya Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 0.13 3.43 - -

Competitive Comparison of Coya Therapeutics's Gross Profit

For the Biotechnology subindustry, Coya Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coya Therapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coya Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Coya Therapeutics's Gross Profit falls into.


;
;

Coya Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Coya Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=3.554 - 0
=3.55

Coya Therapeutics's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=0.002 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.55 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Coya Therapeutics's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0.002
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Coya Therapeutics  (NAS:COYA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Coya Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


Coya Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Coya Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Coya Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Executives
David S Snyder officer: Chief Financial Officer ONE SCIENCE COURT, MADISON WI 53711
Fred Grossman officer: Chief Medical Officer C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Ann Lee director C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Dieter Weinand director C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Goldstein Dov A Md director
Adrian Hepner officer: Chief Medical Officer C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Hideki Garren director C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Anabella Villalobos director C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Howard Berman director, 10 percent owner, officer: Chief Executive Officer C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Bertex Llc 10 percent owner 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057